Contact: Stephanie Abraham, email@example.com, 202-375-6296“The American College of Cardiology supports Congress’s decision to reauthorize FDA’s user fees for devices and prescription drugs. Appropriate funding allows the FDA to provide oversight and to review and approve new treatments in a timely manner,” said ACC President William Zoghbi, MD, FACC in a statement.
“Innovative treatments have played a pivotal role in reducing deaths due to cardiovascular disease in recent decades. It is important to support a system that encourages the development of new medications and devices. The College commends Congress for taking steps to improve post market surveillance of medical devices and increase the use of data registries to improve patient care and device safety. The agreement is excellent for patient health, the future of medical science and continued advances in the field of cardiology.”
About the American College of Cardiology
The American College of Cardiology is transforming cardiovascular care and improving heart health through continuous quality improvement, patient-centered care, payment innovation and professionalism. The College is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers, and bestows credentials upon cardiovascular specialists who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. More information about the association is available online at www.cardiosource.org/ACC.